TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33097687

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin (3.4 mg/kg, every 3 weeks)
Number of subjects: 25
Study: 33097974

Group type: EXPERIMENTAL
Intervention: 3D convolutional neural network (CNN) for automatic segmentation of total metabolic tumour volume (TMTV)
Number of subjects: 733
Study: 33098195

Group type: EXPERIMENTAL
Intervention: Neoadjuvant carboplatin (AUC 6) every 28 days for four cycles plus nab-paclitaxel (100 mg/m2)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Neoadjuvant carboplatin and nab-paclitaxel
Number of subjects: 69
Study: 33098526

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 150
Study: 33098548

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 589

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 589
Study: 33098553

Group type: EXPERIMENTAL
Intervention: Women with increased BMI
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Men with increased BMI
Number of subjects: 493
Study: 33099491

Group type: EXPERIMENTAL
Intervention: Isotoxic hypofractionated concurrent chemoradiotherapy with docetaxel plus lobaplatin
Number of subjects: 30
Study: 33099499

Group type: EXPERIMENTAL
Intervention: Unmet healthcare needs assessed via a standardised telephone assessment within 1 to 4 weeks after hospital discharge
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Quality of life, cognitive impairment, depression, anxiety, and post-traumatic stress disorder
Number of subjects: 200
Study: 33099636

Group type: EXPERIMENTAL
Intervention: HAT TRICK intervention
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Facilitators' experiences
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Future programme refinements
Number of subjects: 62
Study: 33099678

Group type: EXPERIMENTAL
Intervention: arfolitixorin (at four dose levels)
Number of subjects: 33
Study: 33099681

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 1023
Study: 33099742

Group type: EXPERIMENTAL
Intervention: Lobeglitazone (0.5 mg for 24 weeks)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Pioglitazone (15 mg for 24 weeks)
Number of subjects: 205
Study: 33100036

Group type: EXPERIMENTAL
Intervention: LVAD support combined with standardized pharmacological therapy and cardiac function monitoring protocol
Number of subjects: 40
Study: 33100059

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using Dexcom G4 Platinum
Number of subjects: 60
Study: 33100426

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no CBT)
Number of subjects: 110
Study: 33101027

Group type: EXPERIMENTAL
Intervention: Patch containing Allium cepa and allantoin
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Patch containing Allium cepa and allantoin (Group B)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 93
Study: 33101068

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Services-as-usual control condition
Number of subjects: 204
Study: 33101079

Group type: EXPERIMENTAL
Intervention: Probiotics (De Simone Formulation)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 33101178

Group type: EXPERIMENTAL
Intervention: REMOTE Ischemic Perconditioning
Number of subjects: 0
Study: 33101409

Group type: EXPERIMENTAL
Intervention: Lower SHBG levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SHBG as a predictor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SHBG <26.75 mmol/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SHBG levels
Number of subjects: 0
Study: 33101530

Group type: EXPERIMENTAL
Intervention: Cortical activity during first-person virtual reality simulation of bicycle riding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cortical activity at rest
Number of subjects: 0
Study: 33101775

Group type: EXPERIMENTAL
Intervention: Tivozanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 33102224

Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy and systemic therapy, specific details not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group details not available.
Number of subjects: 0
Study: 33102391

Group type: EXPERIMENTAL
Intervention: 2 biopsy cores from PI-RADS 3 lesions
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: 3 biopsy cores from PI-RADS 3 lesions
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: 4 biopsy cores from PI-RADS 3 lesions
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: 2 biopsy cores from PI-RADS 4 lesions
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: 3 biopsy cores from PI-RADS 4 lesions
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: 4 biopsy cores from PI-RADS 4 lesions
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: 2 biopsy cores from PI-RADS 5 lesions
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: 3 biopsy cores from PI-RADS 5 lesions
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: 4 biopsy cores from PI-RADS 5 lesions
Number of subjects: 418
Study: 33102398

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy with mFOLFIRINOX (10 cycles)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Duodenocephalopancreasectomy after chemotherapy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Second-line therapy after 8 months from surgery due to liver and lung metastases
Number of subjects: 1
Study: 33102510

Group type: EXPERIMENTAL
Intervention: Fermented whey concentrate (FWC) drink rich in L-(+)-Lactic acid, consumed daily
Number of subjects: 18
Study: 33102611

Group type: EXPERIMENTAL
Intervention: Democritus Digital Acuity Reading Test (DDART)
Number of subjects: 100

Group type: COMPARATOR
Intervention: MNREAD-GR
Number of subjects: 100
Study: 33103032

Group type: EXPERIMENTAL
Intervention: 150-mg once-monthly risedronate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33103200

Group type: EXPERIMENTAL
Intervention: Baloxavir
Number of subjects: 84672

Group type: COMPARATOR
Intervention: Oseltamivir (Control)
Number of subjects: 84672

Group type: COMPARATOR
Intervention: Zanamivir (Control)
Number of subjects: 84672

Group type: COMPARATOR
Intervention: Laninamivir (Control)
Number of subjects: 84672
Study: 33103545

Group type: EXPERIMENTAL
Intervention: ProGlide
Number of subjects: 2583

Group type: COMPARATOR
Intervention: Prostar XL
Number of subjects: 2583
Study: 33103591

Group type: EXPERIMENTAL
Intervention: Asthma-COPD overlap (ACO) patients
Number of subjects: 2003

Group type: COMPARATOR
Intervention: COPD patients
Number of subjects: 2003

Group type: COMPARATOR
Intervention: Asthma patients
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: ACO patients
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: Diagnosis of ACO
Number of subjects: 2003
Study: 33104001

Group type: EXPERIMENTAL
Intervention: Biological age model
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Principal component analysis
Number of subjects: 100
Study: 33104014

Group type: EXPERIMENTAL
Intervention: LiverMultiScan (mpMRI) as a standardized diagnostic test for liver disease
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Standard care for NAFLD
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: LiverMultiScan (mpMRI)
Number of subjects: 1072
Study: 33104056

Group type: EXPERIMENTAL
Intervention: High levels of hs-CRP
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Higher levels of VAT
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Worsening hs-CRP
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Improved hs-CRP
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Decreased VAT
Number of subjects: 237
Study: 33104201

Group type: EXPERIMENTAL
Intervention: Active S. stercoralis infection
Number of subjects: 668
Study: 33104796

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 25 mg twice daily for induction, followed by 10 mg twice daily for subsequent cycles, combined with decitabine 20 mg/m2 for 5 consecutive days in a 28-day cycle.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ruxolitinib and decitabine combination treatment.
Number of subjects: 25
Study: 33104838

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 46
Study: 33104865

Group type: EXPERIMENTAL
Intervention: Endocannabinoids (ECs), N-acylethanolamines (NAEs), and N-acylphosphatidylethanolamines (NAPEs) concentrations in ileal fluids and plasma
Number of subjects: 35
Study: 33104944

Group type: EXPERIMENTAL
Intervention: Parental locus of control for injury prevention (measured by four items adapted from the Parental Health Beliefs Scales)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Parental locus of control for injury prevention over time (measured at 2, 6, 9, 12, and 24 months)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Injury-related LOC items
Number of subjects: 452
Study: 33104972

Group type: EXPERIMENTAL
Intervention: Zirconium-89 conjugated Pembrolizumab
Number of subjects: 0
Study: 33105036

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 39
Study: 33105234

Group type: EXPERIMENTAL
Intervention: School-based telemedicine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adherence interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electronic adherence sensors
Number of subjects: 0
Study: 33105385

Group type: EXPERIMENTAL
Intervention: Sildenafil treatment for 4 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study: 33105397

Group type: EXPERIMENTAL
Intervention: PrEP (9% coverage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ART (83% coverage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PrEP (47% coverage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ART (88% coverage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TasP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PrEP and TasP combined scale-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: TasP scale-up alone
Number of subjects: 0
Study: 33105456

Group type: EXPERIMENTAL
Intervention: Operative management of SSIs
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Nonoperative management of SSIs
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Superficial SSIs
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Deep or organ/space SSIs
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Overall SSI resolution
Number of subjects: 325
Study: 33106665

Group type: EXPERIMENTAL
Intervention: Precision medicine treatment based on prospective genomic profiling
Number of subjects: 0
Study: 33107003

Group type: EXPERIMENTAL
Intervention: Mailed FIT outreach program with customized electronic health record tools and clinical staff training.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Centralized implementation team and advance mailing of introduction letter.
Number of subjects: 8
Study: 33107145

Group type: EXPERIMENTAL
Intervention: 4-circulating miRNA prognostic model (miR21, miR130b, miR155, miR28)
Number of subjects: 504

Group type: COMPARATOR
Intervention: High-risk group based on 4-circulating miRNA model
Number of subjects: 504
Study: 33107191

Group type: EXPERIMENTAL
Intervention: Dimension 3 scores in early AKI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dimension 3 scores in TCMR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dimension 3 scores in kidneys from older donors
Number of subjects: 0
Study: 33107189

Group type: EXPERIMENTAL
Intervention: NGS platforms
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High-sensitivity PCR-based methodologies
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Different quantitative methods
Number of subjects: 72

Group type: COMPARATOR
Intervention: Samples with MAF ≤ 0.5%
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Patients with brain metastases
Number of subjects: 72
Study: 33107237

Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 1453

Group type: COMPARATOR
Intervention: Non-monetary incentive for referral
Number of subjects: 1453
Study: 33107400

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma with electromagnetic stimulation
Number of subjects: 0
Study: 33107430

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 33107561

Group type: EXPERIMENTAL
Intervention: Heartmate 3 (HM3)
Number of subjects: 540
Study: 33107592

Group type: COMPARATOR
Intervention: Aldosterone antagonists (selective (eplerenone), non-selective (spironolactone or canrenone), or non-steroidal mineralocorticoid antagonists (finerenone)) in combination with ACEi or ARB
Number of subjects: 5745
Study: 33107798

Group type: EXPERIMENTAL
Intervention: Super-resolution US
Number of subjects: 62

Group type: COMPARATOR
Intervention: Contrast-enhanced US
Number of subjects: 62
Study: 33107835

Group type: COMPARATOR
Intervention: rTMS sessions alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: rTMS sessions plus iCBT
Number of subjects: 100
Study: 33107983

Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478) at 50 mg, 75 mg, 100 mg, and 125 mg orally 3 times per week plus dexamethasone at 24 mg twice daily on days 1 to 5 every other week in a 28-day cycle.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Crenigacestat plus dexamethasone
Number of subjects: 36
Study: 33108031

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM) - Confirm Rx ICM implanted, programmed for VT ≥160 bpm for ≥8 intervals, AF ≥2 min, bradycardia ≤40 bpm or pause ≥3.0 s
Number of subjects: 30
Study: 33108238

Group type: EXPERIMENTAL
Intervention: Nivolumab alone (arm A)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Ipilimumab (arm B)
Number of subjects: 83
Study: 33108243

Group type: EXPERIMENTAL
Intervention: Imetelstat
Number of subjects: 57
Study: 33108270

Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) treatment with ≥6-hour use
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) treatment with ≥4-hour use
Number of subjects: 45

Group type: COMPARATOR
Intervention: IPF-OSA group
Number of subjects: 45

Group type: COMPARATOR
Intervention: IPF group
Number of subjects: 45
Study: 33108543

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice daily
Number of subjects: 871

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 871
Study: 33109210

Group type: EXPERIMENTAL
Intervention: gBRCAm testing
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: HRRm testing
Number of subjects: 341
Study: 33109504

Group type: EXPERIMENTAL
Intervention: Highly processed foods
Number of subjects: 46

Group type: COMPARATOR
Intervention: Minimally processed foods
Number of subjects: 46
Study: 33109505

Group type: EXPERIMENTAL
Intervention: Juice intake (8 oz daily)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Water/Sugar-Free Beverage (SFB) intake (8 oz daily)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Sugar-Sweetened Beverages (SSB) intake (8 oz daily)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Toothbrushing (additional daily event)
Number of subjects: 318
Study: 33109627

Group type: EXPERIMENTAL
Intervention: Ribociclib and letrozole (400 mg of ribociclib and 2.5 mg of letrozole daily)
Number of subjects: 40
Study: 33109637

Group type: EXPERIMENTAL
Intervention: Community health campaigns (CHCs)
Number of subjects: 3299

Group type: COMPARATOR
Intervention: Home-based testing
Number of subjects: 3299
Study: 33109646

Group type: EXPERIMENTAL
Intervention: Cog-Awareness ADL Scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Awareness ADL-task: Basic and Instrumental ADL performance-based test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classic tests on anosognosia and cognitive functions
Number of subjects: 0
Study: 33109665

Group type: EXPERIMENTAL
Intervention: HRQoL at diagnosis measured with the EORTC QLQ-C30
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage and tumour size at diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality-adjusted life years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological distress
Number of subjects: 0
Study: 33109667

Group type: EXPERIMENTAL
Intervention: Blood and imaging biomarkers
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Blood samples taken on days 1-3 for brain-focused biomarkers
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Clinically indicated and timed brain MRI and spectroscopy biomarkers
Number of subjects: 164
Study: 33109675

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) programme with a minimum implementation level of 70%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients who fail to reach the 70% implementation level)
Number of subjects: 0
Study: 33109737

Group type: EXPERIMENTAL
Intervention: RC48-ADC
Number of subjects: 43
Study: 33109741

Group type: EXPERIMENTAL
Intervention: 472-gene model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 99 and 200 gene subsets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FFPE-based classifier
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMS classification
Number of subjects: 0
Study: 33110036

Group type: EXPERIMENTAL
Intervention: Physiologic VMS
Number of subjects: 30
Study: 33110439

Group type: EXPERIMENTAL
Intervention: Milk protein concentrate with BC30 (MPCBC30)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Milk protein concentrate without BC30 (MPC)
Number of subjects: 30
Study: 33110445

Group type: EXPERIMENTAL
Intervention: Children with high SDQ scores (≥ 14)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Children with low SDQ scores (< 14)
Number of subjects: 148
Study: 33110590

Group type: EXPERIMENTAL
Intervention: Preoperative testing based on symptoms or suspicious radiologic findings recommended in local guidelines
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Universal testing for every surgical patient
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: In-hospital COVID-19 infection reporting
Number of subjects: 936
Study: 33110623

Group type: EXPERIMENTAL
Intervention: Intense upper limb intervention
Number of subjects: 16
Study: 33110622

Group type: EXPERIMENTAL
Intervention: High dose cholecalciferol (1600 IU/day for < 1 year, 2400 IU/day for > 1 year)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care cholecalciferol (< 1 year = 400 IU/day, > 1 year = 600 IU/day)
Number of subjects: 41
Study: 33110944

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0
Study: 33111240

Group type: EXPERIMENTAL
Intervention: PRIM-ER intervention education components
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: PRIM-ER intervention
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Baseline survey assessing attitudes and knowledge on end-of-life care
Number of subjects: 197
Study: 33111650

Group type: EXPERIMENTAL
Intervention: Loneliness
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Drug use
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Overall mental health and substance use symptoms
Number of subjects: 1008
Study: 33112227

Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire with BMI threshold of 27.5 kg/m² for Chinese and Indian patients
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire with BMI threshold of 35 kg/m² for Malay and Caucasian patients
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: STOP-Bang threshold of 4 or greater
Number of subjects: 1205
Study: 33112242

Group type: EXPERIMENTAL
Intervention: ePRO follow-up using a weekly questionnaire evaluating symptoms and an urgency algorithm for alerts.
Number of subjects: 37
Study: 33112424

Group type: COMPARATOR
Intervention: Physical activity promotion, exercise training, and inspiratory muscle training
Number of subjects: 924
Study: 33112968

Group type: EXPERIMENTAL
Intervention: Haploidentical stem cell transplantation (haploSCT) using KIR-ligand mismatched donor with reduced-intensity conditioning and post-transplantation cyclophosphamide (PTCY) for GVHD prophylaxis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional allogeneic stem cell transplantation (alloSCT)
Number of subjects: 12
Study: 33113214

Group type: EXPERIMENTAL
Intervention: Combined CCNU/TMZ therapy
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: qMSP ratio
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: qMSP, PSQ, MGMT-STP27
Number of subjects: 129
Study: 33114652

Group type: EXPERIMENTAL
Intervention: Atu027 (0.235 mg/kg twice weekly) + Gemcitabine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Atu027 (0.235 mg/kg once weekly) + Gemcitabine
Number of subjects: 23
Study: 33115269

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diets (LCDs)
Number of subjects: 2226

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2226
Study: 33115374

Group type: EXPERIMENTAL
Intervention: 0.2 mg amiselimod
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 0.4 mg amiselimod
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 0.2 mg and 0.4 mg amiselimod
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Amiselimod
Number of subjects: 17
Study: 33115382

Group type: EXPERIMENTAL
Intervention: EDAS plus intensive medical management (IMM)
Number of subjects: 52
Study: 33115815

Group type: EXPERIMENTAL
Intervention: Everolimus, Letrozole, and Trastuzumab
Number of subjects: 32
Study: 33115822

Group type: EXPERIMENTAL
Intervention: Late pregnancy (LP)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Early post partum (EPP)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Late post partum (LPP)
Number of subjects: 8
Study: 33115826

Group type: EXPERIMENTAL
Intervention: Addition of plasma lipids to traditional risk factors
Number of subjects: 0
Study: 33115891

Group type: EXPERIMENTAL
Intervention: Chest and thumb ECG system Coala Heart Monitor, monitored two times per day for 28 days
Number of subjects: 100